Related Experiment Video
Updated: Jul 2, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
A principled approach to non-discrimination in cost-effectiveness
Darius N Lakdawalla1, Jason N Doctor2
1Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, USA. dlakdawa@usc.edu.
New methods for assessing prescription drug value, like EVL and HYT, are flawed and inconsistent. Generalized Risk-Adjusted Cost-Effectiveness (GRACE) offers a microeconomically sound alternative for non-discriminatory drug pricing.
Area of Science:
- Health economics
- Pharmacoeconomics
- Health policy analysis
Background:
- The US Inflation Reduction Act (IRA) restricts discriminatory value assessment methods for Medicare drug price negotiations.
- This necessitates alternative approaches to evaluate prescription drug value fairly, particularly for vulnerable populations.
Purpose of the Study:
- To evaluate proposed non-discriminatory value assessment methods: Equal Value of Life-Years Gained (EVL) and Healthy Years in Total (HYT).
- To propose an alternative method grounded in microeconomic principles for fair drug value assessment.
Main Methods:
- Analysis of microeconomic foundations for EVL and HYT.
- Identification of inconsistencies in EVL and HYT decision-making over time.
- Development of Generalized Risk-Adjusted Cost-Effectiveness (GRACE) as a proposed alternative.
Main Results:
- EVL and HYT lack robust microeconomic underpinnings.
- These methods exhibit inconsistencies, including issues with additivity, indirect comparisons, negative value of survival gains for certain groups, unbounded average gains, and non-convex preferences.
- GRACE offers a theoretically sound alternative.
Conclusions:
- Existing proposed methods (EVL, HYT) for non-discriminatory drug value assessment are theoretically flawed and practically inconsistent.
- Generalized Risk-Adjusted Cost-Effectiveness (GRACE), based on sound microeconomic principles, is proposed as a superior alternative for fair prescription drug pricing evaluations.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Ethical Issues
Ethical Concerns in Healthcare:
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Bias in Epidemiological Studies

